MY172303A - Compositions and methods of use of phorbol esters - Google Patents
Compositions and methods of use of phorbol estersInfo
- Publication number
- MY172303A MY172303A MYPI20093116A MYPI20093116A MY172303A MY 172303 A MY172303 A MY 172303A MY PI20093116 A MYPI20093116 A MY PI20093116A MY PI20093116 A MYPI20093116 A MY PI20093116A MY 172303 A MY172303 A MY 172303A
- Authority
- MY
- Malaysia
- Prior art keywords
- hiv
- methods
- compositions
- phorbol ester
- inhibiting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002644 phorbol ester Substances 0.000 title abstract 4
- 150000004633 phorbol derivatives Chemical class 0.000 title 1
- 230000000120 cytopathologic effect Effects 0.000 abstract 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 102000006481 HIV Receptors Human genes 0.000 abstract 1
- 108010083930 HIV Receptors Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 208000001388 Opportunistic Infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- -1 derivative compound Chemical class 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/46—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom rings with more than six members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89881007P | 2007-01-31 | 2007-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172303A true MY172303A (en) | 2019-11-21 |
Family
ID=39674428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20093116A MY172303A (en) | 2007-01-31 | 2008-01-30 | Compositions and methods of use of phorbol esters |
| MYPI2017001013A MY186986A (en) | 2007-01-31 | 2008-01-30 | Compositions and methods of use of phorbol esters |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017001013A MY186986A (en) | 2007-01-31 | 2008-01-30 | Compositions and methods of use of phorbol esters |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US20080226589A1 (enExample) |
| EP (2) | EP2170053A4 (enExample) |
| JP (5) | JP2010516813A (enExample) |
| KR (2) | KR20120091267A (enExample) |
| CN (1) | CN101677542B (enExample) |
| AU (1) | AU2008211081A1 (enExample) |
| BR (1) | BRPI0806863B8 (enExample) |
| CA (1) | CA2676551C (enExample) |
| CY (1) | CY1117938T1 (enExample) |
| ES (1) | ES2584327T3 (enExample) |
| HR (1) | HRP20160902T1 (enExample) |
| HU (1) | HUE029954T2 (enExample) |
| IL (1) | IL200141A0 (enExample) |
| LT (1) | LT2368555T (enExample) |
| MX (1) | MX2009008179A (enExample) |
| MY (2) | MY172303A (enExample) |
| PH (1) | PH12017502257A1 (enExample) |
| PL (1) | PL2368555T3 (enExample) |
| PT (1) | PT2368555T (enExample) |
| RS (1) | RS54988B1 (enExample) |
| RU (1) | RU2472511C2 (enExample) |
| SI (1) | SI2368555T1 (enExample) |
| WO (1) | WO2008094657A1 (enExample) |
| ZA (1) | ZA200905273B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11564901B2 (en) | 2007-01-31 | 2023-01-31 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters |
| US9974764B2 (en) | 2007-01-31 | 2018-05-22 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| US11696908B2 (en) | 2007-01-31 | 2023-07-11 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US9636317B2 (en) | 2007-01-31 | 2017-05-02 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US10369222B2 (en) | 2012-01-18 | 2019-08-06 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| MY172303A (en) | 2007-01-31 | 2019-11-21 | Biosuccess Biotech Co Ltd | Compositions and methods of use of phorbol esters |
| SG196784A1 (en) | 2008-12-03 | 2014-02-13 | Scripps Research Inst | Stem cell cultures |
| US8575216B2 (en) * | 2009-08-04 | 2013-11-05 | Rutgers, The State University Of New Jersey | Method of treatment for acute myelogenous leukemia |
| EP2804601B1 (en) * | 2012-01-18 | 2025-04-02 | Biosuccess Biotech Co. Ltd. | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases |
| US10099996B2 (en) | 2012-01-18 | 2018-10-16 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| TWI619494B (zh) * | 2013-01-18 | 2018-04-01 | 華鴻新藥股份有限公司 | 巴豆酯之組成物及使用方法 |
| US9550722B2 (en) | 2012-01-18 | 2017-01-24 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbal esters for the treatment of stroke |
| RU2488400C1 (ru) * | 2012-03-12 | 2013-07-27 | Вячеслав Владимирович Чеботарёв | Способ превентивного дифференцированного лечения лиц, контактных с больными заразной формой сифилиса |
| WO2014078350A1 (en) | 2012-11-15 | 2014-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating patients infected with hiv and htlv |
| TWI630909B (zh) * | 2013-01-18 | 2018-08-01 | 華鴻新藥股份有限公司 | 用於中風治療之巴豆酯組成物及使用方法 |
| MA40904A (fr) * | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US6080784A (en) * | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| DE69130063T2 (de) * | 1990-05-30 | 1999-02-25 | The United States of America, represented by the Secretary, U.S. Department of Commerce, Washington, D.C. | Antivirales arzneimittel enthaltend prostratin |
| DE69131667D1 (de) * | 1990-07-30 | 1999-11-04 | Procyon Pharm Inc | Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| US6184248B1 (en) | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| GB9620390D0 (en) | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
| US6063814A (en) * | 1997-04-14 | 2000-05-16 | Chang; Richard L. | Phorbol esters as anti-neoplastic and white blood cell elevating agents |
| CA2237877A1 (en) | 1998-06-26 | 1999-12-26 | Anthony Paolitto | Chest retractor for performing cardiac surgery |
| JP4110347B2 (ja) | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| JP2001139468A (ja) * | 1999-11-11 | 2001-05-22 | Lead Chemical Co Ltd | 抗ウイルス作用を有するホルボール誘導体 |
| WO2001082927A1 (en) * | 2000-05-02 | 2001-11-08 | Lead Chemical Co., Ltd | Antibiral compositions containing phorbol derivatives as the main active ingredient |
| JP2004505047A (ja) | 2000-07-28 | 2004-02-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 複合治療による癌治療 |
| US20070009529A1 (en) | 2002-03-26 | 2007-01-11 | New York University | Agents that dissolve arterial thrombi |
| US20080004332A1 (en) | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| AU2003242405A1 (en) | 2003-05-22 | 2004-12-13 | Lead Chemical Co., Ltd. | Compounds and preparaitons having antiviral effect |
| JP4006645B2 (ja) * | 2003-08-27 | 2007-11-14 | トヨタ自動車株式会社 | 排ガス浄化装置 |
| JP2005179201A (ja) * | 2003-12-16 | 2005-07-07 | Japan Science & Technology Agency | 抗ｈｉｖ化合物とその利用 |
| JP2008069182A (ja) | 2004-03-24 | 2008-03-27 | Yamasa Shoyu Co Ltd | ４’−ｃ−置換−２−ハロアデノシン誘導体 |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| EP1924548B1 (en) * | 2005-07-13 | 2018-03-28 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| MY172303A (en) | 2007-01-31 | 2019-11-21 | Biosuccess Biotech Co Ltd | Compositions and methods of use of phorbol esters |
| EP2030631A1 (en) | 2007-08-31 | 2009-03-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for treating peripheral and cardiovascular diseases via modulation of arteriogenesis |
| US8575216B2 (en) | 2009-08-04 | 2013-11-05 | Rutgers, The State University Of New Jersey | Method of treatment for acute myelogenous leukemia |
| KR101144327B1 (ko) | 2010-04-02 | 2012-05-11 | 한국과학기술연구원 | Ｐｋｃ 작용 활성제를 유효성분으로 함유하는 압상스 간질의 예방 및 치료용 조성물 |
| WO2011127288A2 (en) | 2010-04-07 | 2011-10-13 | La Jolla Institute For Allergy And Immunology | Methods and uses of nur77 and nur77 agonists to modulate macrophages and monocytes, and treat inflammation, inflammatory disease and cardiovascular disease |
| WO2011144901A1 (en) | 2010-05-20 | 2011-11-24 | The University Of Newcastle Upon Tyne | Expansion and directed differentiation of epidermal neural crest stem cells |
| EP2804601B1 (en) | 2012-01-18 | 2025-04-02 | Biosuccess Biotech Co. Ltd. | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases |
| JP5738207B2 (ja) * | 2012-01-27 | 2015-06-17 | 三菱電機株式会社 | 圧縮機、冷蔵庫、機器 |
-
2008
- 2008-01-30 MY MYPI20093116A patent/MY172303A/en unknown
- 2008-01-30 BR BRPI0806863A patent/BRPI0806863B8/pt not_active IP Right Cessation
- 2008-01-30 MX MX2009008179A patent/MX2009008179A/es active IP Right Grant
- 2008-01-30 PL PL10015894T patent/PL2368555T3/pl unknown
- 2008-01-30 ES ES10015894.8T patent/ES2584327T3/es active Active
- 2008-01-30 WO PCT/US2008/001299 patent/WO2008094657A1/en not_active Ceased
- 2008-01-30 JP JP2009548304A patent/JP2010516813A/ja active Pending
- 2008-01-30 KR KR1020127014050A patent/KR20120091267A/ko not_active Ceased
- 2008-01-30 CN CN200880010630.XA patent/CN101677542B/zh not_active Expired - Fee Related
- 2008-01-30 EP EP08725016A patent/EP2170053A4/en not_active Withdrawn
- 2008-01-30 KR KR1020097018188A patent/KR101187859B1/ko not_active Expired - Fee Related
- 2008-01-30 HU HUE10015894A patent/HUE029954T2/en unknown
- 2008-01-30 PT PT100158948T patent/PT2368555T/pt unknown
- 2008-01-30 MY MYPI2017001013A patent/MY186986A/en unknown
- 2008-01-30 RS RS20160571A patent/RS54988B1/sr unknown
- 2008-01-30 SI SI200831648A patent/SI2368555T1/sl unknown
- 2008-01-30 RU RU2009132345/15A patent/RU2472511C2/ru active
- 2008-01-30 AU AU2008211081A patent/AU2008211081A1/en not_active Abandoned
- 2008-01-30 EP EP10015894.8A patent/EP2368555B1/en active Active
- 2008-01-30 LT LTEP10015894.8T patent/LT2368555T/lt unknown
- 2008-01-30 CA CA2676551A patent/CA2676551C/en not_active Expired - Fee Related
- 2008-01-31 US US12/023,753 patent/US20080226589A1/en not_active Abandoned
-
2009
- 2009-07-29 IL IL200141A patent/IL200141A0/en active IP Right Grant
- 2009-07-29 ZA ZA200905273A patent/ZA200905273B/xx unknown
-
2013
- 2013-03-11 US US13/794,467 patent/US9132113B2/en not_active Expired - Fee Related
- 2013-07-26 JP JP2013155621A patent/JP5923068B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-20 US US14/545,061 patent/US20150202178A1/en not_active Abandoned
- 2015-08-12 US US14/824,688 patent/US9603825B2/en not_active Expired - Fee Related
- 2015-09-03 US US14/756,365 patent/US20150374656A1/en not_active Abandoned
-
2016
- 2016-01-08 JP JP2016002526A patent/JP2016056192A/ja active Pending
- 2016-07-19 CY CY20161100709T patent/CY1117938T1/el unknown
- 2016-07-19 HR HRP20160902TT patent/HRP20160902T1/hr unknown
-
2017
- 2017-02-10 US US15/429,311 patent/US9907775B2/en active Active
- 2017-12-08 JP JP2017235841A patent/JP6616387B2/ja active Active
- 2017-12-11 PH PH12017502257A patent/PH12017502257A1/en unknown
-
2018
- 2018-11-05 US US16/180,881 patent/US20190071387A1/en not_active Abandoned
-
2019
- 2019-11-07 JP JP2019202032A patent/JP2020037569A/ja active Pending
-
2020
- 2020-03-09 US US16/812,770 patent/US20200207696A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172303A (en) | Compositions and methods of use of phorbol esters | |
| AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| MX2013005478A (es) | Compuestos heterociclicos condensados antivirales. | |
| MX2013001204A (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| PE20121524A1 (es) | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos | |
| EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
| MY157860A (en) | Prevention and treatment of secondary infections following viral infection | |
| WO2010084115A3 (en) | Antiviral agents | |
| UA91678C2 (en) | Synergism of galactooligosaccharides and polyfructose | |
| WO2008057253A3 (en) | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| EA201100814A1 (ru) | Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| MX2010002735A (es) | Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno. | |
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| MA35443B1 (fr) | Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c | |
| MX2009008495A (es) | Novedosos analogos de nucleosidos para el tratamiento de infecciones virales. | |
| ATE534652T1 (de) | Phosphono-pent-2-en-1-yl-nukleoside und analoga |